Peripheral arterial disease and revascularization of the diabetic foot

Diabetes, Obesity and Metabolism

Volumn 17, Issue 5, 2015, Pages 435-444

  Forsythe, R O ^a   Brownrigg, J ^b   Hinchliffe, R J ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Diabetes complications

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; OSTEOPROTEGERIN; VASODILATOR AGENT;

ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BYPASS SURGERY; CELL THERAPY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; HUMAN; HYPERBARIC OXYGEN; LEG REVASCULARIZATION; MICROCIRCULATION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; WOUND HEALING; COMPLICATION; FOOT; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; VASCULAR CALCIFICATION; VASCULARIZATION;

DIABETIC FOOT; FOOT; HUMANS; MICROCIRCULATION; PERIPHERAL ARTERIAL DISEASE; VASCULAR CALCIFICATION;

EID: 84926217037     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12422     Document Type: Review

References (109)

1. Prompers L, Huijberts M, Apelqvist J et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50: 18-25.
2. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
3. Diabetes UK. State of the Nation 2012: England. 2012. Available from URL: http://www.diabetes.org.uk/documents/reports/state-of-the-nation-2012.pdf. Accessed 16 November 2014.
4. Prompers L, Huijberts M, Apelqvist J et al. Delivery of care to diabetic patients with foot ulcers in daily practice: results of the Eurodiale Study, a prospective cohort study. Diabet Med 2008; 25: 700-707.
5. Hinchliffe RJ, Andros G, Apelqvist J et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev 2012; 28(S1): 179-217.
6. Jeffcoate WJ. Wound healing - a practical algorithm. Diabetes Metab Res Rev 2012; 28: 85-88.
7. Elgzyri T, Larsson J, Thörne J, Eriksson K-F, Apelqvist J. Outcome of ischemic foot ulcer in diabetic patients who had no invasive vascular intervention. Eur J Vasc Endovasc Surg 2013; 46: 110-117.
8. Brownrigg JRW, Davey J, Holt PJ et al. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia 2012; 55: 2906-2912.
9. Tesfaye S, Chaturvedi N, Eaton SEM et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
10. Brownrigg JRW, de Lusignan S, McGovern A et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart 2014; 100: 1837-1843.
11. Klein BEK, Klein R, McBride PE et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med 2004; 164: 1917-1924.
12. Walters DP, Catling W, Mullee MA, Hill RD. The distribution and severity of diabetic foot disease: a community study with comparison to a non-diabetic group. Diabet Med 1992; 9: 354-358.
13. Boyko EJ, Ahroni JH, Cohen V, Nelson KM, Heagerty PJ. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care 2006; 29: 1202-1207.
14. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2008; 168: 2440-2447.
15. Martin CL, Albers J, Herman WH et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-344.
16. Brodeur MR, Bouvet C, Bouchard S et al. Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes. PLoS One 2014; 9: e85922.
17. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17: 3472-3481.
18. Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037.
19. Goldenberg S, Alex M, Joshi RA, Blumenthal HT. Nonatheromatous peripheral vascular disease of the lower extremity in diabetes mellitus. Diabetes 1959; 8: 261-273.
20. Moore JM, Frew ID. Peripheral vascular lesion in diabetes mellitus. Br Med J 1965; 2: 19-23.
21. Ferrier TM. Vascular lesions in diabetes. Br Med J 1965; 2: 819.
22. Aagenaes O, Moe H. Light- and electron-microscopic study of skin capillaries of diabetics. Diabetes 1961; 10: 253-259.
23. Banson BB, Lacy PE. Diabetic microangiopathy in human toes; with emphasis on the ultrastuctural change in dermal capillaries. Am J Pathol 1964; 45: 41-58.
24. Weber HW, Wicht CL. The peripheral angiopathy of diabetics. A plethysmographic and histopathological study. S Afr J Lab Clin Med 1962; 8: 83-93.
25. Ferrier TM. Comparative study of arterial disease in amputated lower limbs from diabetics and non-diabetics (with special reference to feet arteries). Med J Aust 1967; 1: 5-11.
26. Logerfo FW, Coffman JD. Vascular and microvascular disease of the foot in diabetes: implications for foot care. N Engl J Med 1984; 311: 1615-1619.
27. Arora S, Pomposelli F, Logerfo FW, Veves A. Cutaneous microcirculation in the neuropathic diabetic foot improves significantly but not completely after successful lower extremity revascularization. J Vasc Surg 2002; 35: 501-505.
28. Sidawy AN. Diabetic Foot. Philadelphia: Lippincott Williams & Wilkins, 2006.
29. Wyss CR, Matsen FA, Simmons CW, Burgess EM. Transcutaneous oxygen tension measurements on limbs of diabetic and nondiabetic patients with peripheral vascular disease. Surgery 1984; 95: 339-346.
30. Baynes JW, Thorpe SR. The role of oxidative stress in diabetic complications. Curr Opin Endocrinol Diabetes Obes 1996; 3: 277-284.
31. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
32. Schramm TK, Gislason GH, Køber L et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117: 1945-1954.
33. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28: 2901-2907.
34. Lukovits TG, Mazzone TM, Gorelick TM. Diabetes mellitus and cerebrovascular disease. Neuroepidemiology 1999; 18: 1-14.
35. Arboix A, Rivas A, García-Eroles L, de Marcos L, Massons J, Oliveres M. Cerebral infarction in diabetes: clinical pattern, stroke subtypes, and predictors of in-hospital mortality. BMC Neurol 2005; 5: 9.
36. Olsson T, Viitanen M, Asplund K, Eriksson S, Hägg E. Prognosis after stroke in diabetic patients. A controlled prospective study. Diabetologia 1990; 33: 244-249.
37. Young MJ, McCardle JE, Randall LE, Barclay JI. Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management. Diabetes Care 2008; 31: 2143-2147.
38. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
39. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003; 91: 30H-37H.
40. Matthew J, Budoff KMG. Expert review on coronary calcium. Vasc Health Risk Manag 2008; 4: 315-324.
41. Rennenberg RJMW, Kessels AGH, Schurgers LJ, van Engelshoven JMA, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 2009; 5: 185-197.
42. Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 2013; 93: 365-373.
43. Soor GS, Vukin I, Leong SW, Oreopoulos G, Butany J. Peripheral vascular disease: who gets it and why? A histomorphological analysis of 261 arterial segments from 58 cases. Pathology 2008; 40: 385-391.
44. Aragón-Sánchez J, Lázaro-Martínez JL. Factors associated with calcification in the pedal arteries in patients with diabetes and neuropathy admitted for foot disease and its clinical significance. Int J Low Extrem Wounds 2013; 12: 252-255.
45. Huang C-L, Wu I-H, Wu Y-W et al. Association of lower extremity arterial calcification with amputation and mortality in patients with symptomatic peripheral artery disease. PLoS One 2014; 9: e90201.
46. Guzman RJ, Brinkley DM, Schumacher PM, Donahue RMJ, Beavers H, Qin X. Tibial artery calcification as a marker of amputation risk in patients with peripheral arterial disease. J Am Coll Cardiol 2008; 51: 1967-1974.
47. Persy V, De Broe M, Ketteler M. Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 2006; 70: 1537-1538.
48. Nitta K, Akiba T, Suzuki K et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004; 44: 680-688.
49. Scottish Intercollegiate Guidelines Network. SIGN 116. Management of diabetes. A national clinical guideline. 2010. Available from URL: http://www.sign.ac.uk/pdf/sign116.pdf. Accessed 16 November 2014.
50. National Institute for Health and Clinical Excellence. NICE guidelines [CG119] diabetic foot problems. 2011. Available from URL: http://www.nice.org.uk/guidance/cg119/resources/guidance-diabetic-foot-problems-pdf. Accessed 16 November 2014.
51. Leese GP, Reid F, Green V et al. Stratification of foot ulcer risk in patients with diabetes: a population-based study. Int J Clin Pract 2006; 60: 541-545.
52. Diabetes UK. Putting feet first. Fast track for a foot attack: reducing amputations. 2013.
53. Boyko EJ, Ahroni JH, Davignon D, Stensel V, Prigeon RL, Smith DG. Diagnostic utility of the history and physical examination for peripheral vascular disease among patients with diabetes mellitus. J Clin Epidemiol 1997; 50: 659-668.
54. Suzuki E, Kashiwagi A, Nishio Y et al. Increased arterial wall stiffness limits flow volume in the lower extremities in type 2 diabetic patients. Diabetes Care 2001; 24: 2107-2114.
55. Høyer C, Sandermann J, Petersen LJ. The toe-brachial index in the diagnosis of peripheral arterial disease. J Vasc Surg 2013; 58: 231-238.
56. Cina C, Katsamouris A, Megerman J et al. Utility of transcutaneous oxygen tension measurements in peripheral arterial occlusive disease. J Vasc Surg 1984; 1: 362-371.
57. Ruangsetakit C, Chinsakchai K, Mahawongkajit P, Wongwanit C, Mutirangura P. Transcutaneous oxygen tension: a useful predictor of ulcer healing in critical limb ischaemia. J Wound Care 2010; 19: 202-206.
58. van der Feen C, Neijens FS, Kanters SDJM, Mali WPTM, Stolk RP, Banga JD. Angiographic distribution of lower extremity atherosclerosis in patients with and without diabetes. Diabet Med 2002; 19: 366-370.
59. Graziani L, Silvestro A, Bertone V et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg 2007; 33: 453-460.
60. van Golde JM, Ruiter MS, Schaper NC et al. Impaired collateral recruitment and outward remodeling in experimental diabetes. Diabetes 2008; 57: 2818-2823.
61. Rosfors S, Eriksson M, Höglund N, Johansson G. Duplex ultrasound in patients with suspected aorto-iliac occlusive disease. Eur J Vasc Surg 1993; 7: 513-517.
62. Dorweiler B, Neufang A, Kreitner K-F, Schmiedt W, Oelert H. Magnetic resonance angiography unmasks reliable target vessels for pedal bypass grafting in patients with diabetes mellitus. J Vasc Surg 2002; 35: 766-772.
63. Menke J, Larsen J. Meta-analysis: accuracy of contrast-enhanced magnetic resonance angiography for assessing steno-occlusions in peripheral arterial disease. Ann Intern Med 2010; 153: 325-334.
64. Lees T, Troëng T, Thomson IA etal. International variations in infrainguinal bypass surgery - A VASCUNET report. Eur J Vasc Endovasc Surg 2012; 44: 185-192.
65. Moxey PW, Hofman D, Hinchliffe RJ, Jones K, Thompson MM, Holt PJE. Trends and outcomes after surgical lower limb revascularization in England. Br J Surg 2011; 98: 1373-1382.
66. Schaper NC, Andros G, Apelqvist J et al. Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2012; 28: 218-224.
67. Schaper NC, Andros G, Apelqvist J et al. Specific guidelines for the diagnosis and treatment of peripheral arterial disease in a patient with diabetes and ulceration of the foot 2011. Diabetes Metab Res Rev 2012; 28(S1): 236-237.
68. Norgren L, Hiatt WR, Dormandy JA. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33: S1-S75.
69. Krishnan S, Nash F, Baker N, Fowler D, Rayman G. Reduction in diabetic amputations over 11 years in a defined U.K. population benefits of multidisciplinary team work and continuous prospective audit. Diabetes Care 2008; 31: 99-101.
70. Bradbury AW, Adam DJ, Bell J et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg 2010; 51(5 Suppl): 18S-31S.
71. Neville RF, Steinberg J, Babrowicz J, Laredo J, Deaton D, Attinger CE. SS16. A comparison of endovascular revascularization and bypass in regards to healing rates of ischaemic wounds. J Vasc Surg 2010; 51: 11S-12.
72. Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg 2004; 27: 357-362.
73. Taylor GI, Palmer JH. The vascular territories (angiosomes) of the body: experimental study and clinical applications. Br J Plast Surg 1987; 40: 113-141.
74. Biancari F, Juvonen T. Angiosome-targeted lower limb revascularization for ischemic foot wounds: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2014; 47: 517-522.
75. Söderström M, Albäck A, Biancari F, Lappalainen K, Lepäntalo M, Venermo M. Angiosome-targeted infrapopliteal endovascular revascularization for treatment of diabetic foot ulcers. J Vasc Surg 2013; 57: 427-435.
76. Kabra A, Suresh KR, Vivekanand V, Vishnu M, Sumanth R, Nekkanti M. Outcomes of angiosome and non-angiosome targeted revascularization in critical lower limb ischemia. J Vasc Surg 2013; 57: 44-49.
77. Varela C, Acín F, de Haro J, Bleda S, Esparza L, March JR. The role of foot collateral vessels on ulcer healing and limb salvage after successful endovascular and surgical distal procedures according to an angiosome model. Vasc Endovasc Surg 2010; 44: 654-660.
78. Sumpio BE, Forsythe RO, Ziegler KR, van Baal JG, Lepantalo MJA, Hinchliffe RJ. Clinical implications of the angiosome model in peripheral vascular disease. J Vasc Surg 2013; 58: 814-826.
79. Forsythe R, Hinchliffe R. Commentary on "Angiosome-targeted lower limb revascularization for ischaemic foot wounds: systematic review and meta-analysis". Eur J Vasc Endovasc Surg 2014; 47: 523.
80. Kechagias A, Perälä J, Ylönen K, Mahar MAA, Biancari F. Validation of the Finnvasc score in infrainguinal percutaneous transluminal angioplasty for critical lower limb ischemia. Ann Vasc Surg 2008; 22: 547-551.
81. Dick F, Diehm N, Galimanis A, Husmann M, Schmidli J, Baumgartner I. Surgical or endovascular revascularization in patients with critical limb ischemia: influence of diabetes mellitus on clinical outcome. J Vasc Surg 2007; 45: 751-761.
82. Ballotta E, Toniato A, Piatto G, Mazzalai F, Da Giau G. Lower extremity arterial reconstruction for critical limb ischemia in diabetes. J Vasc Surg 2014; 59: 708-719.
83. Awad S, Karkos CD, Serrachino-Inglott F et al. The impact of diabetes on current revascularisation practice and clinical outcome in patients with critical lower limb ischaemia. Eur J Vasc Endovasc Surg 2006; 32: 51-59.
84. Singh N, Sidawy AN, DeZee KJ, Neville RF, Akbari C, Henderson W. Factors associated with early failure of infrainguinal lower extremity arterial bypass. J Vasc Surg 2008; 47: 556-561.
85. Calle-Pascual AL, Durán A, Diaz A et al. Comparison of peripheral arterial reconstruction in diabetic and non-diabetic patients: a prospective clinic-based study. Diabetes Res Clin Pract 2001; 53: 129-136.
86. Elgzyri T, Larsson J, Nyberg P, Thörne J, Eriksson K-F, Apelqvist J. early revascularization after admittance to a diabetic foot center affects the healing probability of ischemic foot ulcer in patients with diabetes. Eur J Vasc Endovasc Surg 2014; 48: 440-446.
87. Albers M, Romiti M, Brochado-Neto FC, De Luccia N, Pereira CAB. Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg 2006; 43: 498-503.
88. Faglia E, Dalla Paola L, Clerici G et al. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg 2005; 29: 620-627.
89. Forsythe RO, Jones KG, Hinchliffe RJ. Distal bypasses in patients with diabetes and infrapopliteal disease: technical considerations to achieve success. Int J Low Extrem Wounds 2014; 13: 347-362.
90. Keymel S, Heinen Y, Balzer J et al. Characterization of macro-and microvascular function and structure in patients with type 2 diabetes mellitus. Am J Cardiovasc Dis 2011; 1: 68-75.
91. Gili M, Orsello A, Gallo S, Brizzi MF. Diabetes-associated macrovascular complications: cell-based therapy a new tool? Endocrine 2013; 44: 557-575.
92. Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 2005; 90: 315-326.
93. Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427-435.
94. Porat Y, Assa-Kunik E, Belkin M et al. A novel potential therapy for vascular diseases: blood-derived stem/progenitor cells specifically activated by dendritic cells. Diabetes Metab Res Rev 2014; 30: 623-634.
95. Lederman RJ, Mendelsohn FO, Anderson RD et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359: 2053-2058.
96. Teraa M, Sprengers RW, van der Graaf Y, Peters CEJ, Moll FL, Verhaar MC. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013; 258: 922-929.
97. Schaper NC, Havekes B. Diabetes: impaired damage control. Diabetologia 2012; 55: 18-20.
98. Yan J, Tie G, Xu TY, Cecchini K, Messina LM. Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy. Stem Cell Rev 2013; 9: 360-372.
99. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 2011; 53: 445-453.
100. Lambert MA, Belch JJF. Medical management of critical limb ischaemia: where do we stand today? J Intern Med 2013; 274: 295-307.
101. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication; mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4: 297-306.
102. Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology 2011; 62: 15-17.
103. Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. A placebo controlled multicenter study. Norwegian Pentoxifylline Multicenter Trial Group. Int Angiol 1996; 15: 75-80.
104. Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010; 33: 998-1003.
105. Stoekenbroek RM, Santema TB, Legemate DA, Ubbink DT, van den Brink A, Koelemay MJW. Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review. Eur J Vasc Endovasc Surg 2014; 47: 647-655.
106. Bishop AJ, Mudge E. A retrospective study of diabetic foot ulcers treated with hyperbaric oxygen therapy. Int Wound J 2012; 9: 665-676.
107. Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2012; 4: CD004123.
108. Arvela E, Söderström M, Korhonen M et al. Finnvasc score and modified prevent III score predict long-term outcome after infrainguinal surgical and endovascular revascularization for critical limb ischemia. J Vasc Surg 2010; 52: 1218-1225.
109. Moxey PW, Brownrigg J, Kumar SS et al. The BASIL survival prediction model in patients with peripheral arterial disease undergoing revascularization in a university hospital setting and comparison with the FINNVASC and modified PREVENT scores. J Vasc Surg 2013; 57: 1-7.